Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of pretreatment clinical characteristics and hematologic biomarkers for prognosticating response to pembrolizumab in patients with metastatic UC. PUBMED®, Web of Science™, and Scopus® databases were searched for articles published before May 2021 according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) statement. Studies were deemed eligible if they evaluated overall survival (OS) in patients with metastatic urothelial carcinoma treated with pembrolizumab and pretreatment clinical characteristics or laboratory examination. Overall, 13 studies comprising 1311 patients were eligible for the meta-analysis. Several pretreatment patients' demographics and hematologic biomarkers were significantly associated with worse OS as follows: Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥ 2 (Pooled hazard ratio [HR]: 3.24, 95% confidence interval [CI] 2.57-4.09), presence of visceral metastasis (Pooled HR: 1.84, 95% CI 1.42-2.38), presence of liver metastasis (Pooled HR: 4.23, 95% CI 2.18-8.20), higher neutrophil-lymphocyte ratio (NLR) (Pooled HR: 1.29, 95% CI 1.07-1.55) and, higher c-reactive protein (CRP) (Pooled HR: 2.49, 95% CI 1.52-4.07). Metastatic UC patients with poor PS, liver metastasis, higher pretreatment NLR and/or CRP have a worse survival despite pembrolizumab treatment. These findings might help to guide the prognostic tools for clinical decision-making; however, they should be interpreted carefully, owing to limitations regarding the retrospective nature of primary data.

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Wahringer Gurtel 43 18 20 1090 Vienna Austria

Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia

Department of Urology King Faisal Medical City Abha Saudi Arabia

Department of Urology Luzerner Kantonsspital Lucerne Switzerland

Department of Urology Medical University of Silesia Zabrze Poland

Department of Urology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University Hospital Zurich Zurich Switzerland

Department of Urology University Medical Centre Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Division of Urology Department of Special Surgery Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Men's Health and Reproductive Health Research Center Shahid Beheshti University of Medical Sciences Tehran Iran

Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran

Zobrazit více v PubMed

Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654. PubMed DOI

Flaig TW, Spiess PE, Agarwal N, et al. Bladder cancer, version 3. 2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(3):329–354. doi: 10.6004/jnccn.2020.0011. PubMed DOI

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi: 10.1056/NEJMoa1613683. PubMed DOI PMC

Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104. doi: 10.1016/j.eururo.2020.03.055. PubMed DOI

Lundgren KT, Farina MS, Bellmunt J. Pembrolizumab in the treatment of advanced urothelial cancer. Future Oncol. 2017;13(30):2745–2758. doi: 10.2217/fon-2017-0284. PubMed DOI

Bronimann S, Lemberger U, Bruchbacher A. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. Curr Opin Urol. 2020;30(4):519–526. doi: 10.1097/MOU.0000000000000776. PubMed DOI

Ertl IE, Shariat SF, Mostafaei H. Fibroblast growth factor receptors across urothelial carcinoma landscape. Curr Opin Urol. 2020;30(4):557–565. doi: 10.1097/MOU.0000000000000782. PubMed DOI

Kardoust Parizi M, Margulis V, Lotan Y. Fibroblast growth factor receptor: a systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. Urol Oncol. 2021 doi: 10.1016/j.urolonc.2021.01.025. PubMed DOI

Schmidinger M, Resch I, Fajkovic H. Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma? Curr Opin Urol. 2021;31(3):270–275. doi: 10.1097/MOU.0000000000000874. PubMed DOI

Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi: 10.1038/nature14011. PubMed DOI PMC

Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074. doi: 10.1158/1078-0432.CCR-13-3271. PubMed DOI PMC

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi: 10.1056/NEJMoa1200690. PubMed DOI PMC

Mori K, Abufaraj M, Mostafaei H, et al. The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol. 2021;79(6):783–792. doi: 10.1016/j.eururo.2020.10.006. PubMed DOI

Lavoie JM, Black PC, Eigl BJ. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. J Urol. 2019;202(1):49–56. doi: 10.1097/JU.0000000000000136. PubMed DOI

Massari F, Di Nunno V. Atezolizumab for platinum-treated metastatic urothelial carcinoma. Lancet. 2018;391(10122):716–718. doi: 10.1016/S0140-6736(17)33298-1. PubMed DOI

Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–757. doi: 10.1016/S0140-6736(17)33297-X. PubMed DOI

Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi: 10.1056/NEJMoa1606774. PubMed DOI

Xiang X, Yu PC, Long D, et al. Prognostic value of PD -L1 expression in patients with primary solid tumors. Oncotarget. 2018;9(4):5058–5072. doi: 10.18632/oncotarget.23580. PubMed DOI PMC

Zhao T, Li C, Wu Y. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS ONE. 2017;12(4):e0176822. doi: 10.1371/journal.pone.0176822. PubMed DOI PMC

Fan Z, Liang Y, Yang X, et al. A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer. Onco Targets Ther. 2019;12:1791–1801. doi: 10.2147/OTT.S186271. PubMed DOI PMC

Mori K, Pradere B, Moschini M, et al. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2021;151:35–48. doi: 10.1016/j.ejca.2021.03.049. PubMed DOI

Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474. doi: 10.3389/fimmu.2018.01474. PubMed DOI PMC

Mariathasan S, Turley SJ, Nickles D, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi: 10.1038/nature25501. PubMed DOI PMC

Xylinas E, Robinson BD, Kluth LA, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014;40(1):121–127. doi: 10.1016/j.ejso.2013.08.023. PubMed DOI

Apolo AB, Ostrovnaya I, Halabi S, et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013;105(7):499–503. doi: 10.1093/jnci/djt015. PubMed DOI PMC

Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–3181. doi: 10.1200/JCO.1999.17.10.3173. PubMed DOI

Bellmunt J, Albanell J, Paz-Ares L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002;95(4):751–757. doi: 10.1002/cncr.10762. PubMed DOI

De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–199. doi: 10.1200/JCO.2011.37.3571. PubMed DOI PMC

Galsky MD, Moshier E, Krege S, et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013;119(16):3012–3019. doi: 10.1002/cncr.28146. PubMed DOI

Sengelov L, Kamby C, von der Maase H. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol. 2001;39(6):634–642. doi: 10.1159/000052520. PubMed DOI

Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–1855. doi: 10.1200/JCO.2009.25.4599. PubMed DOI

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi: 10.1371/journal.pmed.1000100. PubMed DOI PMC

DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28(2):105–114. doi: 10.1016/j.cct.2006.04.004. PubMed DOI

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2. PubMed DOI

Etani T, Naiki T, Sugiyama Y, et al. Low geriatric nutritional risk index as a poor prognostic marker for second-line pembrolizumab treatment in patients with metastatic urothelial carcinoma: a retrospective multicenter analysis. Oncology. 2020;98(12):876–883. doi: 10.1159/000508923. PubMed DOI

Fujiwara M, Yuasa T, Urasaki T, et al. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: a retrospective single-center analysis in Japan. Cancer Rep. 2021;1:1. doi: 10.1002/cnr2.1398. PubMed DOI PMC

Fukuokaya W, Kimura T, Yanagisawa T, et al. Impact of dose-effect in smoking on the effectiveness of pembrolizumab in patients with metastatic urothelial carcinoma. Target Oncol. 2021;16(2):189–196. doi: 10.1007/s11523-020-00786-y. PubMed DOI

Furubayashi N, Kuroiwa K, Tokuda N, et al. Treating japanese patients with pembrolizumab for platinum-refractory advanced urothelial carcinoma in real-world clinical practice. J Clin Med Res. 2020;12(5):300–306. doi: 10.14740/jocmr4162. PubMed DOI PMC

Inoue S, Sassa N, Kato T, et al. Presence of constipation predicts the therapeutic efficacy of pembrolizumab in metastatic urothelial cancer patients. Int J Urol. 2020;27(12):1116–1123. doi: 10.1111/iju.14367. PubMed DOI

Ishiyama Y, Kondo T, Nemoto Y, et al. Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. Anticancer Res. 2021;41(3):1607–1614. doi: 10.21873/anticanres.14922. PubMed DOI

Kadono Y, Kawaguchi S, Nohara T, et al. Blood cell count biomarkers predicting efficacy of pembrolizumab as second-line therapy for advanced urothelial carcinoma. Anticancer Res. 2021;41(3):1599–1606. doi: 10.21873/anticanres.14921. PubMed DOI

Kijima T, Yamamoto H, Saito K, et al. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2021;70(3):657–665. doi: 10.1007/s00262-020-02709-2. PubMed DOI PMC

Kobayashi T, Ito K, Kojima T, et al. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci. 2021;112(2):760–773. doi: 10.1111/cas.14762. PubMed DOI PMC

Ogihara K, Kikuchi E, Shigeta K, et al. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Urol Oncol. 2020;38(6):602.e1. doi: 10.1016/j.urolonc.2020.02.005. PubMed DOI

Shimizu T, Miyake M, Hori S, et al. Clinical impact of sarcopenia and inflammatory/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with pembrolizumab. Diagnostics (Basel) 2020 doi: 10.3390/diagnostics10050310. PubMed DOI PMC

Tamura D, Jinnouchi N, Abe M, et al. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice. Int J Clin Oncol. 2020;25(5):899–905. doi: 10.1007/s10147-019-01613-9. PubMed DOI

Yamamoto Y, Yatsuda J, Shimokawa M, et al. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Int J Clin Oncol. 2021;26(1):169–177. doi: 10.1007/s10147-020-01784-w. PubMed DOI

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655. doi: 10.1097/00000421-198212000-00014. PubMed DOI

Nakamura Y, Kitano S, Takahashi A, et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. 2016;7(47):77404–77415. doi: 10.18632/oncotarget.12677. PubMed DOI PMC

Khaki AR, Li A, Diamantopoulos LN, et al. Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with checkpoint inhibitors. Cancer. 2020;126(6):1208–1216. doi: 10.1002/cncr.32645. PubMed DOI PMC

Parikh RB, Galsky MD, Gyawali B, et al. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: insights from real-world practice. Oncologist. 2019;24(6):e397–e399. doi: 10.1634/theoncologist.2019-0039. PubMed DOI PMC

Bilen MA, Dutcher GMA, Liu Y, et al. Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab. Clin Genitourin Cancer. 2018;16(3):e563–e575. doi: 10.1016/j.clgc.2017.12.015. PubMed DOI PMC

Chasseuil E, Saint-Jean M, Chasseuil H, et al. Blood predictive biomarkers for nivolumab in advanced melanoma. Acta Derm Venereol. 2018;98(4):406–410. doi: 10.2340/00015555-2872. PubMed DOI

Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732–738. doi: 10.1093/annonc/mdw016. PubMed DOI

Jeyakumar G, Kim S, Bumma N, et al. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5(1):82. doi: 10.1186/s40425-017-0287-5. PubMed DOI PMC

Park W, Lopes G. Perspectives: neutrophil-to-lymphocyte ratio as a potential biomarker in immune checkpoint inhibitor for non-small-cell lung cancer. Clin Lung Cancer. 2019;20(3):143–147. doi: 10.1016/j.cllc.2018.12.003. PubMed DOI

Zaragoza J, Caille A, Beneton N, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol. 2016;174(1):146–151. doi: 10.1111/bjd.14155. PubMed DOI

Mori K, Miura N, Mostafaei H, et al. Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(8):1459–1474. doi: 10.1007/s10147-020-01690-1. PubMed DOI PMC

Kargl J, Busch SE, Yang GH, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381. doi: 10.1038/ncomms14381. PubMed DOI PMC

Gooden MJ, de Bock GH, Leffers N. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. doi: 10.1038/bjc.2011.189. PubMed DOI PMC

Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1–7. doi: 10.1016/j.lungcan.2017.01.013. PubMed DOI

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239. PubMed DOI PMC

Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–163. doi: 10.2217/fon.09.136. PubMed DOI

Saito K, Kawakami S, Ohtsuka Y, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007;100(2):269–273. doi: 10.1111/j.1464-410X.2007.06934.x. PubMed DOI

Krajsova I, Arenberger P, Lakomy R, et al. Long-term survival with ipilimumab: experience from a national expanded access program for patients with melanoma. Anticancer Res. 2015;35(11):6303–6310. PubMed

Simeone E, Gentilcore G, Giannarelli D, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014;63(7):675–683. doi: 10.1007/s00262-014-1545-8. PubMed DOI PMC

Fujii T, Naing A, Rolfo C, et al. Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2018;130:108–120. doi: 10.1016/j.critrevonc.2018.07.010. PubMed DOI

Sonpavde G, Pond GR, Rosenberg JE, et al. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. J Urol. 2016;195(2):277–282. doi: 10.1016/j.juro.2015.07.111. PubMed DOI PMC

Sonpavde G, Manitz J, Gao C, et al. Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors. J Urol. 2020;204(6):1173–1179. doi: 10.1097/JU.0000000000001199. PubMed DOI PMC